Shopping Cart 0
Cart Subtotal
AED 0

Xellia Pharmaceuticals ApS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Xellia Pharmaceuticals ApS (Xellia), a subsidiary of Novo A/S is a healthcare products provider that offers fermented and semi-synthetic APIs and injectable finished dosage forms. The company offers strain and fermentation development with bacteria and fungi. It provides injectable products in the form of liquids, aseptically filled dry powders or in the form of freeze-dried powders; and inhalable products. Xellia offers products in therapeutic areas including gram-negative infections, gram-positive infections, resistance scare in healthcare, pathogenic microorganisms and fungal infections. The company operates manufacturing facilities in Denmark, the US, Hungary and China. Xellia is headquartered in Copenhagen, Denmark.

Xellia Pharmaceuticals ApS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 11

Partnerships 12

Leukocare and Xellia Pharma Enter into Partnership Agreement 12

Xellia Pharma, SINTEF Materials And Statens Serum Institut Enter Into Agreement To Develop New Antibiotics 13

Acquisition 14

Novo Acquires Xellia Pharma for USD700 Million 14

Xellia Pharmaceuticals ApS-Key Competitors 16

Xellia Pharmaceuticals ApS-Key Employees 17

Xellia Pharmaceuticals ApS-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Joint Venture 18

Recent Developments 19

Strategy And Business Planning 19

Sep 18, 2018: Xellia Pharmaceuticals Opens North American Commercial Office in Chicago Ahead of Launching Value-Added Anti-Infective Injectable Drug Products 19

Oct 11, 2017: Xellia Pharmaceuticals Expands its Global Specialty Anti-infective Product Manufacturing Capabilities with a USD 25m Investment in its Copenhagen Site 21

Aug 22, 2017: Xellia Pharmaceuticals Completes Expansion of its Budapest Facilities, Strengthening its Global Anti-infective Product Capabilities 22

Financial Announcements 23

Mar 21, 2018: Xellia Pharmaceuticals Reports on Strong 2017 Financial Results and Advances in the Development of its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag 23

Corporate Communications 24

Jun 13, 2018: Xellia Pharmaceuticals Names Matthew Anderson As Chief Financial Officer 24

Other Significant Developments 25

Jan 18, 2017: Xellia Pharmaceuticals Signs Davos Declaration on Combating Antimicrobial Resistance 25

Appendix 26

Methodology 26

About GlobalData 26

Contact Us 26

Disclaimer 26


List Of Figure

List of Figures

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Key Facts 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xellia Pharmaceuticals ApS, Deals By Therapy Area, 2012 to YTD 2018 8

Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 11

Leukocare and Xellia Pharma Enter into Partnership Agreement 12

Xellia Pharma, SINTEF Materials And Statens Serum Institut Enter Into Agreement To Develop New Antibiotics 13

Novo Acquires Xellia Pharma for USD700 Million 14

Xellia Pharmaceuticals ApS, Key Competitors 16

Xellia Pharmaceuticals ApS, Key Employees 17

Xellia Pharmaceuticals ApS, Subsidiaries 18

Xellia Pharmaceuticals ApS, Joint Venture 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Xellia Pharmaceuticals ApS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Xellia Pharmaceuticals ApS (Xellia), a subsidiary of Novo A/S is a healthcare products provider that offers fermented and semi-synthetic APIs and injectable finished dosage forms. The company offers strain and fermentation development with bacteria and fungi. It provides injectable products in the form of liquids, aseptically filled dry powders or in the form of freeze-dried powders; and inhalable products. Xellia offers products in therapeutic areas including gram-negative infections, gram-positive infections, resistance scare in healthcare, pathogenic microorganisms and fungal infections. The company operates manufacturing facilities in Denmark, the US, Hungary and China. Xellia is headquartered in Copenhagen, Denmark.

Xellia Pharmaceuticals ApS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 11

Partnerships 12

Leukocare and Xellia Pharma Enter into Partnership Agreement 12

Xellia Pharma, SINTEF Materials And Statens Serum Institut Enter Into Agreement To Develop New Antibiotics 13

Acquisition 14

Novo Acquires Xellia Pharma for USD700 Million 14

Xellia Pharmaceuticals ApS-Key Competitors 16

Xellia Pharmaceuticals ApS-Key Employees 17

Xellia Pharmaceuticals ApS-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Joint Venture 18

Recent Developments 19

Strategy And Business Planning 19

Sep 18, 2018: Xellia Pharmaceuticals Opens North American Commercial Office in Chicago Ahead of Launching Value-Added Anti-Infective Injectable Drug Products 19

Oct 11, 2017: Xellia Pharmaceuticals Expands its Global Specialty Anti-infective Product Manufacturing Capabilities with a USD 25m Investment in its Copenhagen Site 21

Aug 22, 2017: Xellia Pharmaceuticals Completes Expansion of its Budapest Facilities, Strengthening its Global Anti-infective Product Capabilities 22

Financial Announcements 23

Mar 21, 2018: Xellia Pharmaceuticals Reports on Strong 2017 Financial Results and Advances in the Development of its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag 23

Corporate Communications 24

Jun 13, 2018: Xellia Pharmaceuticals Names Matthew Anderson As Chief Financial Officer 24

Other Significant Developments 25

Jan 18, 2017: Xellia Pharmaceuticals Signs Davos Declaration on Combating Antimicrobial Resistance 25

Appendix 26

Methodology 26

About GlobalData 26

Contact Us 26

Disclaimer 26


List Of Figure

List of Figures

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Key Facts 2

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Xellia Pharmaceuticals ApS, Deals By Therapy Area, 2012 to YTD 2018 8

Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9

Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 11

Leukocare and Xellia Pharma Enter into Partnership Agreement 12

Xellia Pharma, SINTEF Materials And Statens Serum Institut Enter Into Agreement To Develop New Antibiotics 13

Novo Acquires Xellia Pharma for USD700 Million 14

Xellia Pharmaceuticals ApS, Key Competitors 16

Xellia Pharmaceuticals ApS, Key Employees 17

Xellia Pharmaceuticals ApS, Subsidiaries 18

Xellia Pharmaceuticals ApS, Joint Venture 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Xellia Pharmaceuticals ApS, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.